{"id":"standard-triple","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Standard Triple typically combines two nucleoside reverse transcriptase inhibitors (NRTIs) with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI), working synergistically to block HIV replication at multiple steps. This combination approach reduces the likelihood of resistance development and improves virological suppression compared to monotherapy or dual therapy.","oneSentence":"Standard Triple is a fixed-dose combination of three antiretroviral agents used to suppress HIV replication.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:38:14.253Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve patients"},{"name":"HIV-1 infection in treatment-experienced patients (formulation-dependent)"}]},"trialDetails":[{"nctId":"NCT03546686","phase":"PHASE2","title":"Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-11-12","conditions":"Breast Cancer","enrollment":51},{"nctId":"NCT02954874","phase":"PHASE3","title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-18","conditions":"Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7","enrollment":1155},{"nctId":"NCT06033196","phase":"PHASE2","title":"Tocilizumab in Lung Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"Lung Transplant","enrollment":350},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT04677816","phase":"PHASE2","title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-22","conditions":"Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer","enrollment":50},{"nctId":"NCT07486687","phase":"PHASE3","title":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2026-04","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer","enrollment":1000},{"nctId":"NCT07486089","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)","enrollment":60},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":"Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer","enrollment":700},{"nctId":"NCT04944836","phase":"PHASE2","title":"Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-03-09","conditions":"Rotator Cuff Tears","enrollment":58},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT06318403","phase":"PHASE2","title":"Estradiol Supplementation and Rotator Cuff Repair","status":"NOT_YET_RECRUITING","sponsor":"University of Utah","startDate":"2028-03","conditions":"Rotator Cuff Tears, Rotator Cuff Injuries, Rotator Cuff Syndrome","enrollment":58},{"nctId":"NCT07239739","phase":"NA","title":"Comparing Two Medicines for Healing Jaw Bone Infections After Root Canal Treatment","status":"NOT_YET_RECRUITING","sponsor":"Faiz ur rahman","startDate":"2026-06-15","conditions":"Periapical Lesion, Periapical Periodontitis","enrollment":62},{"nctId":"NCT06833853","phase":"","title":"A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients","status":"RECRUITING","sponsor":"Menarini Silicon Biosystems, INC","startDate":"2026-03-13","conditions":"Metastatic Breast Cancer (MBC)","enrollment":187},{"nctId":"NCT07428642","phase":"","title":"PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-09-01","conditions":"Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer","enrollment":168},{"nctId":"NCT05422794","phase":"PHASE1","title":"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-18","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma","enrollment":57},{"nctId":"NCT07478705","phase":"NA","title":"Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-05-01","conditions":"Triple Negative Breast Cancer, Surveillance, Recurrence","enrollment":30},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT05639556","phase":"","title":"Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2023-04-20","conditions":"Cystic Fibrosis","enrollment":300},{"nctId":"NCT06134375","phase":"PHASE1, PHASE2","title":"A Study of Tetrathiomolybdate (TM) Plus Capecitabine","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2024-11-26","conditions":"Triple Negative Breast Cancer, Residual Disease","enrollment":204},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT07436988","phase":"PHASE1","title":"Affordable Made-in-India Microspheres for Liver Cancer Therapy","status":"NOT_YET_RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2026-02-15","conditions":"Hepatecellular Carcinoma","enrollment":18},{"nctId":"NCT06229392","phase":"PHASE1","title":"A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2026-06-01","conditions":"Breast Cancer, Breast Cancer Triple Negative","enrollment":""},{"nctId":"NCT04333706","phase":"PHASE1, PHASE2","title":"A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)","status":"RECRUITING","sponsor":"University of Southern California","startDate":"2020-09-26","conditions":"Breast, Metastatic, Triple Negative","enrollment":65},{"nctId":"NCT05665348","phase":"PHASE2, PHASE3","title":"Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2023-03-09","conditions":"HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor","enrollment":229},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT06710197","phase":"PHASE2","title":"IL-1 Inhibition in Early TNBC","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2025-03-05","conditions":"Early Stage Triple Negative ER Low Breast Cancer","enrollment":""},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT07439211","phase":"PHASE1","title":"Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2026-07","conditions":"Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT07435961","phase":"NA","title":"Magnetotherapy in Carpal Tunnel Syndrome: Randomized Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Fatih Sultan Mehmet Training and Research Hospital","startDate":"2026-02-01","conditions":"Magnetotherapy, Carpal Tunnel Syndrome (CTS), Median Nerve Compression","enrollment":60},{"nctId":"NCT03808337","phase":"PHASE2","title":"Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-01-16","conditions":"Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer","enrollment":145},{"nctId":"NCT05650723","phase":"PHASE2","title":"Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-08","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":50},{"nctId":"NCT07425808","phase":"PHASE2, PHASE3","title":"FLT3-ITD Targeted Therapy in Fit AML Patients","status":"NOT_YET_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2026-12-01","conditions":"AML (Acute Myeloid Leukemia)","enrollment":230},{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Triple Negative Breast Cancer","enrollment":85},{"nctId":"NCT05977309","phase":"NA","title":"Effect of Topical Ozone on The Healing Diabetic Foot Ulcer","status":"COMPLETED","sponsor":"Asmat Burhan","startDate":"2023-08-01","conditions":"Wound Heal, Diabetic Foot Ulcer, Ozone","enrollment":430},{"nctId":"NCT07300475","phase":"PHASE1","title":"Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-31","conditions":"Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT07407920","phase":"PHASE2","title":"Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma","enrollment":120},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT07401537","phase":"PHASE2","title":"Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-12-31","conditions":"Triple -Negative Breast Cancer, Breast Cancer","enrollment":416},{"nctId":"NCT04966520","phase":"NA","title":"Accelerated Neuromodulation to Alleviate Cognitive Deficits Due to Cancer Therapy","status":"COMPLETED","sponsor":"Sneha Phadke","startDate":"2021-06-01","conditions":"Cancer","enrollment":15},{"nctId":"NCT07233928","phase":"NA","title":"Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2026-02-06","conditions":"Early Breast Cancer, Metastatic Breast Cancer","enrollment":1050},{"nctId":"NCT05528133","phase":"PHASE2","title":"Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-01-25","conditions":"Triple Negative Breast Cancer","enrollment":86},{"nctId":"NCT02962791","phase":"NA","title":"Prospective Randomized Trial Comparing TRIPLE Site ventriculAr Stimulation Versus Conventional Pacing in CRT canDidates","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2017-10-24","conditions":"Cardiac Resynchronization Therapy","enrollment":36},{"nctId":"NCT02876302","phase":"PHASE2","title":"Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-01-24","conditions":"Inflammatory Breast Cancer (IBC)","enrollment":23},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT06199232","phase":"NA","title":"Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University","startDate":"2024-01-23","conditions":"Liver Metastasis Colon Cancer, ctDNA Genotype, MSS","enrollment":47},{"nctId":"NCT07344779","phase":"","title":"A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-02-17","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1600},{"nctId":"NCT06225505","phase":"NA","title":"Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2026-01-05","conditions":"Triple Negative Breast Cancer","enrollment":450},{"nctId":"NCT07357948","phase":"NA","title":"Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Institut Curie","startDate":"2026-08-01","conditions":"Triple Negative Breast Cancer, Non-Metastatic","enrollment":150},{"nctId":"NCT05909332","phase":"PHASE3","title":"Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-20","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":764},{"nctId":"NCT06349486","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2023-11-28","conditions":"Helicobacter Pylori Eradication","enrollment":390},{"nctId":"NCT07341867","phase":"PHASE1","title":"Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype","status":"NOT_YET_RECRUITING","sponsor":"Andrew Hantel, MD","startDate":"2026-06","conditions":"Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation","enrollment":90},{"nctId":"NCT07311083","phase":"NA","title":"Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Kliniken Essen-Mitte","startDate":"2026-02-01","conditions":"Microbiome","enrollment":60},{"nctId":"NCT07334535","phase":"PHASE4","title":"Isa-VRD in TIE HRMM","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-30","conditions":"Multiple Myeloma","enrollment":117},{"nctId":"NCT06351332","phase":"PHASE1, PHASE2","title":"ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Filipa Lynce, MD","startDate":"2024-05-01","conditions":"Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer","enrollment":78},{"nctId":"NCT06962163","phase":"NA","title":"Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients","status":"RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2025-12-05","conditions":"Metastatic Breast Cancer","enrollment":12},{"nctId":"NCT04870515","phase":"NA","title":"Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-11-04","conditions":"Localized Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":20},{"nctId":"NCT05809752","phase":"PHASE1","title":"A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-08-22","conditions":"Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer","enrollment":18},{"nctId":"NCT07315048","phase":"NA","title":"Nursing Risk Management in Emergency SAH Surgery Using Healthcare Failure Mode and Effect Analysis(HFMEA)","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-03-01","conditions":"Spontaneous Subarachnoid Hemorrhage","enrollment":156},{"nctId":"NCT06588205","phase":"","title":"Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2025-05-05","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","enrollment":200},{"nctId":"NCT06022029","phase":"PHASE1","title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","status":"RECRUITING","sponsor":"OncoNano Medicine, Inc.","startDate":"2023-10-13","conditions":"Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma","enrollment":168},{"nctId":"NCT06085274","phase":"NA","title":"Sentinel lympH Node Biopsy With Indocyanine Green in Breast Cancer After NEoadjuvant Chemotherapy (SHINE)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-09-03","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT07292142","phase":"PHASE1, PHASE2","title":"FMT in Triple Negative Breast Cancer Guided by ctDNA","status":"NOT_YET_RECRUITING","sponsor":"Jewish General Hospital","startDate":"2026-02","conditions":"Breast Cancer","enrollment":125},{"nctId":"NCT07290153","phase":"","title":"Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-01","conditions":"Breast Cancer Female NOS, General Anxiety Disorder, Depressive Disorder","enrollment":120},{"nctId":"NCT06809998","phase":"PHASE1, PHASE2","title":"COntralateral CorticoSTeroid Injection in Total Knee Arthroplasty","status":"RECRUITING","sponsor":"Unity Health Toronto","startDate":"2025-01-24","conditions":"Total Knee Anthroplasty, Osteoarthritis(Primary), Osteoarthritis (OA) of the Knee","enrollment":60},{"nctId":"NCT04722978","phase":"PHASE3","title":"Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2021-04-20","conditions":"Triple Negative Breast Cancer","enrollment":228},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT07104318","phase":"PHASE3","title":"Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Helicobacter Pylori","enrollment":360},{"nctId":"NCT06152705","phase":"NA","title":"Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression","status":"RECRUITING","sponsor":"The Royal Ottawa Mental Health Centre","startDate":"2024-09-16","conditions":"Depression, Depressive Disorder, Major, Depressive Episode","enrollment":210},{"nctId":"NCT06492759","phase":"PHASE2","title":"High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-01-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":29},{"nctId":"NCT07031219","phase":"NA","title":"HIV/HBV/HCV Triple Screening in Primary Care","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02-15","conditions":"HIV, HBV (Hepatitis B Virus), HCV","enrollment":50},{"nctId":"NCT06903468","phase":"NA","title":"Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-10-27","conditions":"Ductal Carcinoma in Situ, Breast Cancer","enrollment":50},{"nctId":"NCT02323581","phase":"NA","title":"Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts","status":"RECRUITING","sponsor":"Darren Schneider, M.D.","startDate":"2013-11","conditions":"Aortic Aneurysm, Thoracoabdominal, Aortic Aneurysm, Thoracic, Aortic Dissection, Thoracoabdominal","enrollment":520},{"nctId":"NCT07176533","phase":"NA","title":"Suprazygomatic Maxillary Nerve Block in Pediatric Tonsillectomy","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2026-01-01","conditions":"Tonsillitis","enrollment":60},{"nctId":"NCT07278115","phase":"NA","title":"Effects on Remission of Type 2 Diabetes Mellitus Following Gastric Bypass Alone vs Gastric Bypass Combined With Truncal Vagotomy","status":"NOT_YET_RECRUITING","sponsor":"University Research Institute for the Study of Genetic & Malignant Disorders in Childhood","startDate":"2025-12","conditions":"Diabetes Mellitus Type 2","enrollment":40},{"nctId":"NCT03483012","phase":"PHASE2","title":"Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-05-01","conditions":"Breast Cancer","enrollment":6},{"nctId":"NCT05347134","phase":"PHASE3","title":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2022-06-10","conditions":"Triple Negative Breast Cancer","enrollment":254},{"nctId":"NCT05564650","phase":"PHASE1","title":"Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-01-12","conditions":"Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome","enrollment":6},{"nctId":"NCT06664801","phase":"PHASE2","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-14","conditions":"Pulmonary Arterial Hypertension","enrollment":164},{"nctId":"NCT06925750","phase":"PHASE2","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-12","conditions":"Pulmonary Arterial Hypertension","enrollment":130},{"nctId":"NCT05623397","phase":"","title":"A Deep Learning Method to Evaluate QT on Ribociclib","status":"COMPLETED","sponsor":"CMC Ambroise Paré","startDate":"2023-07-28","conditions":"Breast Cancer, Ribociclib","enrollment":70},{"nctId":"NCT05701475","phase":"NA","title":"Cutibacterium Acnes: Triple Prevention in Shoulder Operations","status":"COMPLETED","sponsor":"Clinique Générale dAnnecy","startDate":"2023-01-18","conditions":"Post-Operative Wound Infection, Surgical Site Infection","enrollment":156},{"nctId":"NCT02688803","phase":"PHASE4","title":"Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)","status":"TERMINATED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-08-30","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT04074720","phase":"","title":"Prospective Breast Cancer Biospecimen Collection","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2018-05-10","conditions":"Breast Cancer, Invasive Breast Cancer, Carcinoma in Situ of the Breast","enrollment":200},{"nctId":"NCT07259733","phase":"NA","title":"Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)","status":"RECRUITING","sponsor":"Instituto Dante Pazzanese de Cardiologia","startDate":"2023-07-15","conditions":"Apparent Resistant Hypertension, Hypertension, High Blood Pressure","enrollment":142},{"nctId":"NCT05180006","phase":"PHASE2","title":"Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2022-02-24","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT05383170","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers","status":"COMPLETED","sponsor":"Cytovation AS","startDate":"2023-03-21","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma","enrollment":6},{"nctId":"NCT07246681","phase":"PHASE3","title":"Lignin in Treatment of Helicobacter Pylori Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2025-10-31","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":70},{"nctId":"NCT05088395","phase":"NA","title":"Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2022-05-19","conditions":"Cancer","enrollment":2050},{"nctId":"NCT04180371","phase":"PHASE1, PHASE2","title":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","status":"ACTIVE_NOT_RECRUITING","sponsor":"BicycleTx Limited","startDate":"2019-11-07","conditions":"Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer","enrollment":288},{"nctId":"NCT06078384","phase":"PHASE2","title":"Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-12-27","conditions":"Triple-negative Breast Cancer","enrollment":354},{"nctId":"NCT05973864","phase":"PHASE2","title":"Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-03-11","conditions":"Triple Negative Breast Neoplasms","enrollment":220},{"nctId":"NCT03979508","phase":"PHASE2","title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2020-01-10","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":26},{"nctId":"NCT06008275","phase":"EARLY_PHASE1","title":"Neratinib in Combination With Ruxolitinib in Patients With mTNBC","status":"RECRUITING","sponsor":"Baylor Research Institute","startDate":"2024-09-16","conditions":"Metastatic Triple-Negative Breast Carcinoma, Breast Cancer","enrollment":20},{"nctId":"NCT02593175","phase":"PHASE2","title":"Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-03","conditions":"Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7","enrollment":43},{"nctId":"NCT07059975","phase":"EARLY_PHASE1","title":"UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML","status":"RECRUITING","sponsor":"Joanna Yi","startDate":"2025-10-22","conditions":"Acute Myeloid Leukemia, Pediatric AML","enrollment":36},{"nctId":"NCT06683092","phase":"","title":"Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2025-05-01","conditions":"Cystic Fibrosis","enrollment":200},{"nctId":"NCT07016399","phase":"PHASE2","title":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","status":"RECRUITING","sponsor":"Vandana Abramson","startDate":"2025-09-09","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma","enrollment":51},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1031,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Standard Triple Therapy for H. pylori","Hp-PAC"],"phase":"marketed","status":"active","brandName":"Standard Triple","genericName":"Standard Triple","companyName":"University of Alberta","companyId":"university-of-alberta","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Standard Triple is a fixed-dose combination of three antiretroviral agents used to suppress HIV replication. Used for HIV-1 infection in treatment-naïve patients, HIV-1 infection in treatment-experienced patients (formulation-dependent).","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}